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Abstract We previously reported that remote limb ischemic
conditioning (RLIC; PERconditioning) during acute stroke
confers neuroprotection, possibly due to increased cerebral
blood flow (CBF). Vascular cognitive impairment (VCI) is a
growing threat to public health without any known treatment.
The bilateral common carotid artery stenosis (BCAS) mouse
model is regarded as the most valid model for VCI. We
hypothesized that RLIC (postconditioning; RIPostC) will aug-
ment CBF during chronic cerebral hypoperfusion (CCH) and
prevent cognitive impairment in the BCAS model. BCAS
using customized microcoil was performed in C57/B6 male
mice to establish CCH. Aweek after the BCAS surgery, mice
were treated with RIPostC-therapy once daily for 2 weeks.
CBF was measured with laser speckle contrast imager at
different time points. Cognitive testing was performed at 4-
week post-BCAS, and brain tissue was harvested for bio-
chemistry. BCAS led to chronic hypoperfusion resulting into
impaired cognitive function as tested by novel object recog-
nition (NOR). Histological examinations revealed that BCAS
triggered inflammatory responses and caused frequent
vacuolization and cell death. BCAS also increased the gener-
ation and accumulation of amyloid beta protein (Aβ),
resulting into the loss of white matter (WM) and myelin basic
protein (MBP). RIPostC-therapy showed both acute increase
as well as sustained improvement in CBF even after the
cessation of therapy for a week. RIPostC improved cognitive
function, inhibited inflammatory responses, prevented the cell
death, reduced the generation and accumulation of Aβ, and
protected WM integrity. RIPostC is effective in the BCAS
model and could be an attractive low-cost conventional
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therapy for aged individuals with VCI. The mechanisms by
which RIPostC improves CBF and attenuates tissue damage
need to be investigated in the future.
Keywords Vascular cognitive impairment . Remote ischemic
postconditioning . Chronic cerebral hypoperfusion . Arterial
stenosis . Transient ischemic attacks .White matter lesion
Introduction
The prevalence of dementia is expected to triple by 2050 [1].
In the past few decades, there has been an “Alzheimerization”
of dementia with a tendency to attribute all cognitive decline
to Alzheimer’s disease (AD) [2]. This view is now being
revised with the recognition of the major vascular contribution
to dementia [1, 3–5]. Vascular cognitive impairment (VCI) is
the term that encompasses the clinical spectrum from mild
cognitive dysfunction to vascular dementia. The NINDS
Stroke Progress Review Group in 2012 cited “prevention of
VCI” as a major research priority (http://www.ninds.nih.gov/
find_people/ninds/OSPP/Stroke-Research-Priorities-
Meeting-2012.htm).
The pathological hallmark of VCI is white matter (WM)
damage from ischemia in the periventricular regions and
centrum semiovale [1, 5]. The imaging correlate of this WM
damage is “leukoaraiosis” [6]. The degree and severity of
leukoaraiosis are associated with cognitive impairment, de-
pression, gait abnormalities, and disability [6]. There is no
known treatment once symptoms appear although observa-
tional studies suggest exercise (probably due to upregulation
of endogenous protection) may slow down cognitive
decline [7]. WM changes are mediated by vascular
dysfunction and inflammation, blood-brain barrier
(BBB) leakage, glial activation and injury to oligoden-
drocytes, and finally demyelination [1]. Reduction in the
cerebral blood flow (CBF) leading to hypoperfusion is
an early and characteristic finding [1].
Remote limb ischemic conditioning (RLIC) is the simple,
inexpensive, and safe use of repetitive inflation-deflation pro-
cedure of a blood pressure (BP) cuff on the arm or leg to
protect distant organs such as the brain, heart, and kidney from
ischemic injury [8]. A number of preclinical studies also
demonstrated that RLIC is effective at reducing injury in focal
cerebral ischemia models (recently reviewed by us) [8]. We
demonstrated that RLIC is protective and increases CBF in a
murine model of thromboembolic stroke [9, 10]. Moreover, in
patients with intracranial arterial stenosis, RLIC increased
CBF as measured by SPECT [11]. Therefore, the mech-
anism of this protection may partially rely on the im-
provement of CBF.
There are a number of proposed animal models for VCI. In
a recent review of all mouse models for VCI and vascular
dementia [12], Bink and colleagues found that the
mouse bilateral common carotid artery stenosis
(BCAS) model to be the best and most valid [13]. This
model reproduces cerebral hypoperfusion, inflammation,
BBB damage, WM damage, and cognitive deficits of
the human condition [13, 14]. It also avoids damage to
the visual pathways, a complication of rat model of
carotid ligation. We hypothesized that remote ischemic
postconditioning (RIPostC) will improve CBF and be-
havioral outcomes and reduce inflammation and WM
damage in this murine BCAS model of VCI.
Materials and Methods
Animals and Experimental Groups
The Institutional Animal Care and Use Committee of Georgia
Regents University (GRU) approved the experimental proce-
dures as per the National Institute of Health guidelines.
C57BL/6 J wild-type male mice (10±1 weeks old) were
procured from Jackson Laboratory (Bar Harbor, Maine) and
were housed in GRU’s AAALAC accredited facility. In these
experiments, we use the term “remote ischemic
postconditioning” (RIPostC) as we start the conditioning
1 week after the VCI procedure for 2-week period. We ran-
domized 20 mice into 3 groups: a sham-operated group for
procedures of BCAS and therapy (Sham group, N=5), an
untreated BCAS/VCI-induced group (with RIPostC sham
procedure), i.e., BCAS group (N=7), and a VCI-induced
RIPostC-treated BCAS + RPostC-group (N=8). The outcome
measures were blinded. Cognitive function and CBF changes
were considered as the primary outcomes to calculate the
sample size of 5 in each group to provide >80 % power at
α=0.05, as reported by us earlier [10].
Experimental Methods
Please see the Online Supplementary Information for the
descriptive methodology. BCAS surgery and laser speckle
contrast imaging (LSCI) were performed in mice sedated with
buprenorphine and under isofluorane anesthesia. To produce
BCAS, customized microcoils specially designed to produce
VCI in the mouse were twined by rotating it around both
common carotid arteries, as reported elsewhere [13]. Bilateral
noninvasive RIPostC therapy or related sham procedure using
a programmable cuff was performed daily for 2-weeks as
reported earlier by us [9]. High-resolution LSCI (PSI system,
Perimed Inc.) was used to image cerebral perfusion at different
time points as indicated in the figure. Behavioral assessment
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by novel object recognition (NOR) test was performed as
reported earlier by us [15]. The capability of the mouse to
discriminate between a familiar versus novel object was de-
termined as the discrimination index, DI=(Tn-Tf )/(Tn+Tf ),
where Tn is the time spent by the mouse with the novel object
and Tf indicates the time spent with the familiar object.
At day 28, brain tissues were harvested after perfu-
sion sacrifice, and the two hemispheres were immedi-
ately separated. One of the hemispheres was fixed in
the chilled buffered formalin (10 %) for neuropathology
and immunostaining, while the other one was snap
frozen in liquid nitrogen for tissue biochemistry. Hema-
toxylin and eosin (HNE) staining was performed to
estimate cell death and score the severity of pathology
as reported by us [16]. Luxol fast blue (LFB)-neutral
red staining was performed to detect the severity of
WM lesion and fiber density [13]. Immunostaining for
myelin basic protein (MBP) and Aβ42 were performed
by using anti-MBP and anti-Aβ antibodies (Santa Cruz
Biotechnology, USA), respectively. ELISA assay for
Aβ42 in the brain tissue was performed using Aβ42
selective commercial kit and following the manufac-
turer’s protocol (AnaSpec, USA). Real-time quantitative
PCR was performed as reported by us [17].
Statistical Analysis
CBF was compared using repeated measure ANOVA
only between the BCAS and BCAS + RIPostC therapy
groups because the Sham group did not undergo any
occlusive procedure, which can affect CBF. Other data
were compared between all three groups using ANOVA.
Wherever mentioned, Means with different letters are
significantly different while “ns” stands for “no signif-
icant” difference (p<0.05).
Results
RIPostC Therapy After BCAS Increases Cerebral Perfusion
and Behavioral Outcome
Figure 1a, b shows that there was no significant difference
between the CBF of BCAS and BCAS + RIPostC groups at
baseline before (295±39 vs 317±28 perfusion unit, PU) and
immediately after (154±20 vs 146±23 PU) the BCAS sur-
gery. Moreover, in agreement with the previous report [13],
there was a slight but insignificant spontaneous improvement
in the CBF of all BCAS groups with time and over days.
However, there was no significant difference between the
CBF of the two groups on day 7 post-BCAS and before
initiating the RIPostC therapy (153±14 vs 155±15 PU). In
comparison to untreated BCAS group, there was a significant
increase (p=0.03) in CBF after 7 days of RIPostC therapy in
the BCAS + RIPostC group when measured the same
day (day 14 post-BCAS) and 1 h after the treatment
(161±10 vs 192±20 PU). We further continued the
RIPostC therapy for 1 week more up to day 21 post-
BCAS, and then discontinued it for the next 1 week.
When measured at day 28, we again found significantly
Fig. 1 Detection of cerebral
blood flow changes by laser
speckle contrast imager (LSCI)
and nonspatial working memory
by novel object (NOR)
recognition. a Representative
contrast and photo overlay images
of cerebral perfusion, b absolute
value of cerebral perfusion in
perfusion unit (PU) where “red”
symbols indicate BCAS group
while “green” symbols are for
BCAS + RIPostC group, and c
time of exploration (Tn) spent
with the novel object, and d the
discrimination index (DI). Data
presented as mean±SD. Pairs of
means with different letters are
significantly different, p<0.05
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(p=0.0001) increased CBF in the BCAS + RIPostC
group as compared to the BCAS group (193±23 vs
265±23 PU). This demonstrates a sustained effect on
the CBF even after the cessation of RIPostC therapy.
We performed NOR test, which reliably evaluates the
nonspatial working memory of the frontal subcortical
region [18]. The results (Fig. 1c, d) show that the Sham
group is more attracted toward a novel object, a char-
acteristic exploratory feature in rodents. On the other
hand, the BCAS group has lesser curiosity toward the
Fig. 2 BCAS triggers vascular
and glial inflammatory responses,
which is attenuated by RIPostC. a
Quantitation of mRNA
expression of ICAM-1 and
VCAM-1 as detected by the
semiquantitative real-time PCR
and normalized to beta-actin as
housekeeping gene. Data are
presented as mean±SD. Pairs of
means with different letters are
significantly different, p<0.05. b,
c Representative immunostaining
images from different regions of
the brain (frontal cortex, corpus
callosum (CC) and hippocampal
CA1 region) as mentioned in the
figure legend, showing activated
glial response as detected by
anti- GFAP and IBA1 antibodies,
respectively (20×)
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exploration of the novel object as evident from the
significantly decreased Tn (p=0.0004) as well as DI
(p<0.0001) in comparison to the Sham group. This
indicates that BCAS causes impairment of discrimina-
tive ability of the mouse toward novelty of an object.
RIPostC therapy in the BCAS + RIPostC group signif-
icantly restored the Tn (p=0.0336) and DI (p=0.0256)
scores as compared to the BCAS group. In conclusion,
the data demonstrate that BCAS results in the loss of
working memory while RIPostC attenuates this deficit.
RIPostC Therapy After BCAS Attenuates Inflammatory
Responses and Aβ42 Accumulation in the Brain
Chronic cerebral hypoperfusion triggers inflammatory re-
sponses, which impair microvascular function, increase gen-
eration of Aβ and decrease its clearance, and cause neurode-
generation deeper into the WM [1, 19–21]. We found that the
gene expression of vascular inflammatory responses (ICAM-1
and VCAM-1) are significantly upregulated in the BCAS
group as compared to Sham (Fig. 2). This subsequently led
to glial activation and inflammation as evident by the in-
creased GFAP staining and IBA-1 expression (Fig. 2). When
treated with RIPostC therapy, the vascular inflammatory re-
sponses were significantly attenuated, and the glial activation
was downregulated.
Increased Aβ generation and resultant accumulation are
one of the major characteristics of dementia and progression
of related AD type pathology [21]. We quantified the
Aβ level in the brain tissue by ELISA and investigated
the accumulation pattern. Figure 3a shows that BCAS in
28 days led to significant generation and accumulation
of Aβ42 (4-fold increase) in the brain of BCAS group
as compared to the Sham group (p<0.0001). RIPostC
therapy for 2 weeks decreased the Aβ42 content (2-fold
decrease) in BCAS + RIPostC-group as compared to
BCAS group (p=0.0051). Since Aβ plaque is a hall-
mark of dementia and AD-type pathology, we next
investigated the expression and accumulation pattern of
Aβ in the different regions of the brain. At 28-day post-
Fig. 3 Progression of Aβ-type
pathology in the brain 28-days
after BCAS and its attenuation by
RIPostC. Data are presented as
mean±SD. Pairs of means with
different letters are significantly
different, p<0.05. a
Quantification of Aβ42 by a
commercial ELISA kit for mouse,
and b, d representative images
showing expression of Aβ in the
different regions of the brain
(frontal cortex and hippocampal
CA1 as well as dentate gyrus
(DG) regions) as detected by anti-
Aβ antibody (20×)
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BCAS, we did not find major plaque formation, but the
expression of Aβ was increased after BCAS in every
region of the brain (Fig. 3b–d). The representative im-
ages from the frontal cortex (an area associated with
Fig. 4 Histopathological changes
in the brain due to BCAS and its
modulation by RIPostC therapy
as detected by the hematoxylin-
eosin (HNE) staining. a
Representative HNE images from
different regions of the brain
(frontal cortex, corpus callosum
(CC), and hippocampal CA1
region) as mentioned in panels
(20×), showing significant
number of vacuoles and pyknotic
dead cells after BCAS, and its
protection by RIPostC, b
quantitation of dead and viable
cells at ×10 magnification in the
cortical region, and c the average
severity score of pathology in the
above regions
Fig. 5 Luxol fast blue (LFB) staining for the detection of white matter
(WM) changes after BCAS and its preservation byRIPostC therapy in the
regions nearby hippocampus and corpus callosum. a Representative
images (2.5×) from sagittal sections of hippocampus showing shrinkage
above the CA1 region (as indicated by black asterisks) after BCAS. b
Corresponding magnified images (×20) of the region below the
hippocampus as indicated by red arrow in each panel, showing signifi-
cant loss in the integrity of WM after BCAS and its augmentation by
RIPostC. c Representative LFB images from the corpus callosum region
showing significant degeneration by BCAS and its protection by RIPostC
which can be more severe during long-term follow-up
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working memory) and the hippocampus show that at
day 28, Aβ started accumulating around the neuronal
cell body in the BCAS group, which was reduced in the
BCAS + RIPostC group.
RIPostC Therapy After BCAS Prevents Cell Death
and Demyelination
HNE staining showed frequent vacuolization and pyknotic
dead cells both in the cortical and WM regions after BCAS
with moderate to severe neuropathological scores in different
regions (Fig. 4) [16, 22]. When counted in the identical
cortical region, % cell death was significantly increased while
% viable cell was decreased in the BCAS group at day 28 as
compared to the Sham. RIPostC therapy for 2 weeks robustly
prevented the cell death and vacuolization in the BCAS +
RIPostC group as compared to the BCAS group. RIPostC
therapy also reduced the average severity score of pathology
in the brain due to BCAS [16].
We next investigated the integrity of WM and chang-
es in the MBP expression in the different regions of the
brain. Representative images (Fig. 5) show severe WM
degeneration, and axonal loss as indicated by changes in
LFB staining occurred after the BCAS in the different
regions of the untreated BCAS group. At 28-day post-
BCAS, such changes were present in the corpus
callosum and hippocampal regions. RIPostC therapy
robustly prevented the WM degeneration. Similarly,
there was a severe loss in MBP expression in the
frontal cortical region of the untreated BCAS group,
which was preserved after RIPostC therapy in the
BCAS + RIPostC group (Fig. 6). Similar to the LFB
staining, changes in the MBP expression were more
prominent in the cortical region compared to other re-
gions in a 28-day survival period.
Discussion
This is the first report in any animal model of VCI where
RLIC has been tested. Our major findings are that RIPostC in
the murine BCAS model improves CBF and cognitive func-
tion and reduces inflammation and neurodegeneration. Long-
term (2 weeks) RIPostC therapy significantly increased the
CBF in a sustained fashion and improved cognitive function.
CBF remain increased for at least 1 week even after the
cessation of long-term RIPostC therapy (Fig. 1). We also
found reduced Aβ level in RIPostC-treated group that might
be attenuated due to the improved CBF and subsequent clear-
ance of Aβ [19]. BCAS in mice triggers a proinflammatory
milieu and impairs microvascular dysfunction, as evident by
the increased gene expression of ICAM-1 and VCAM-1
(Fig. 2) [20]. ICAM-1 and VCAM-1 promote adhesion phe-
nomena resulting into disintegration of BBB and increased
infiltration of proinflammatory immune cells, which amplifies
the neuro-glial inflammation, WM degeneration, and cell
death (Figs. 2, 3, 4, 5, 6). When treated, RIPostC therapy
not only reduced the vascular inflammatory responses but it
also downregulated GFAP (astrocytes) and IBA-1 (microglial)
expressions, subsequently leading to reduced WM changes
and neurodegeneration.
There are no known treatments for VCI. Therapies are
needed to prevent the transition and progression of the disease
process to dementia. A potential target population for RLIC
may be patients with “leukoaraiosis” on MRI. The
Leukoaraiosis and Disability cohort (LADIS) is a European
multicenter collaboration with the aim to predict disability in
the patient aged 65–84 years with leukoaraiosis [6, 22]. These
patients suffer from cognitive impairment, gait instability and
falls, depression, and urinary incontinence. The degree of
leukoaraiosis is associated with cognitive impairment, and the
progression of leukoaraiosis on MRI strongly predicts cogni-
tive decline [23, 24]. There is no known treatment to slow
Fig. 6 Loss in myelin basic
protein (MBP) after BCAS and its
protection by RIPostC therapy. a
Representative images (10×) from
the frontal cortical region
showing significant
vacuolization, and loss in MBP
after BCAS as detected by anti-
MBP immunostaining. b
Representative images from the
area showing CA1 region of
hippocampus (10×)
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down the cognitive decline, but observational studies suggest
that physical activity (which modulates endogenous protection
as well as CBF similar to RLIC) might be of benefit [7]. From
the LADIS cohort, estimates of sample size for a clinical trial
with an intervention to reduce progression of WM changes on
MRI range from 58 to 70, highlighting the potential transla-
tional pathway for RLIC. Moreover, RLIC is feasible for long-
term treatment and comparatively more conventional for aged
individuals with gait problem. A small size Chinese trial re-
ported that RLIC increases CBF in patients suffering from
intracranial arterial stenosis and prevents recurrent stroke [11].
It also demonstrates that this therapy using a BP cuff has long-
term feasibility, as they were able to treat patients for 300 days.
Our study has several limitations. First, our number of
animals is small (N=20), but the study is randomized, blinded,
and adequately powered. The effects observed were robust,
however, indicating that large sample sizes are not needed.
Second, while the BCAS model is regarded as the most valid
for VCI, it does not recapitulate small vessel disease, the
underlying pathophysiology of VCI.While themodel produces
chronic hypoperfusion, it does this via obstruction of the larger
blood vessels affecting microvascular flow but the pathology is
itself not intrinsic in the smaller vessels. Moreover, the disease
process has a defined start whereas in humans, it is insidious
with slow onset. Third, we treated and followed these mice for
a relatively shorter period of time, 28 days. Fourth, we used
young male mice, and VCI is a disease of the elderly. Fifth, in
this translation report, we did not investigate the mechanism of
protection by RIPostC. We now have ongoing work to test
RIPostC therapy in aged mice of both sexes; MRI to see WM
changes, and study the possible mechanism of vascular protec-
tion by long-term RIPostC therapy.
In summary, RIPostC therapy increases CBF and improves
cognitive performance in a murine model of VCI. This ther-
apy is highly translatable to humans. If successful, this no-
additional cost therapy using BP cuff will be an “exercise
equivalent” which will be highly convenient for elderly pa-
tients as well as caretakers to perform, and therefore, may
change the current therapeutic paradigm of VCI in humans.
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